Moreover, the combination of the FABP5‐targeting nanocarrier co‐delivery system with RFA and PD‐L1 monoclonal antibodies demonstrated exceptional efficacy as a therapeutic strategy against HCC. Here, FABP5 is linked to hepatocellular carcinoma.